FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1945841307> ?p ?o ?g. }

• W1945841307 endingPage "1264" @default.
• W1945841307 startingPage "1257" @default.
• W1945841307 abstract "Aims To show that albiglutide, a glucagon-like peptide-1 receptor agonist, is an effective and generally safe treatment to improve glycaemic control in patients with type 2 diabetes mellitus whose hyperglycaemia is inadequately controlled with pioglitazone (with or without metformin). Methods In this 3-year, randomized, double-blind, placebo-controlled study, 310 adult patients on a regimen of pioglitazone (with or without metformin) were randomly assigned to receive additional treatment with albiglutide [30 mg subcutaneous (s.c.) once weekly, n = 155] or matching placebo (n = 155). The primary efficacy endpoint was change from baseline to week 52 (intention-to-treat) in glycated haemoglobin (HbA1c). Results The model-adjusted change from baseline in HbA1c at week 52 was significantly better with albiglutide than with placebo (−0.8%, 95% confidence interval −1.0, −0.6; p < 0.0001). Change from baseline fasting plasma glucose was −1.3 mmol/l in the albiglutide group and +0.4 mmol/l in the placebo group (p < 0.0001); a significantly higher percentage of patients reached the HbA1c goals with albiglutide (p < 0.0001), and the rate of hyperglycaemia rescue up to week 52 for albiglutide was 24.4 versus 47.7% for placebo (p < 0.0001). Albiglutide plus pioglitazone had no impact on weight, and severe hypoglycaemia was observed rarely (n = 2). With few exceptions, the results of safety assessments were similar between the groups, and most adverse events (AEs) were mild or moderate. The 52-week incidence rates for gastrointestinal AEs for albiglutide and placebo were: 31.3 and 29.8%, respectively (diarrhoea: 11.3 and 8.6%; nausea: 10.7 and 11.3%; vomiting: 4.0 and 4.0%). Conclusions Albiglutide 30 mg administered once weekly as an add-on to pioglitazone (with or without metformin) provided effective and durable glucose lowering and was generally well tolerated." @default.
• W1945841307 created "2016-06-24" @default.
• W1945841307 creator A5004846236 @default.
• W1945841307 creator A5005036709 @default.
• W1945841307 creator A5022703304 @default.
• W1945841307 creator A5029406825 @default.
• W1945841307 creator A5033331656 @default.
• W1945841307 creator A5050151766 @default.
• W1945841307 creator A5062849136 @default.
• W1945841307 creator A5089768127 @default.
• W1945841307 date "2014-10-06" @default.
• W1945841307 modified "2023-09-27" @default.
• W1945841307 title "Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled" @default.
• W1945841307 cites W1976503602 @default.
• W1945841307 cites W2007910256 @default.
• W1945841307 cites W2050826565 @default.
• W1945841307 cites W2090244618 @default.
• W1945841307 cites W2097395605 @default.
• W1945841307 cites W2109728760 @default.
• W1945841307 cites W2118805427 @default.
• W1945841307 cites W2128825255 @default.
• W1945841307 cites W2159205789 @default.
• W1945841307 cites W2160001758 @default.
• W1945841307 cites W2172193326 @default.
• W1945841307 cites W2190748907 @default.
• W1945841307 cites W4253801677 @default.
• W1945841307 doi "https://doi.org/10.1111/dom.12382" @default.
• W1945841307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25155146" @default.
• W1945841307 hasPublicationYear "2014" @default.
• W1945841307 type Work @default.
• W1945841307 sameAs 1945841307 @default.
• W1945841307 citedByCount "84" @default.
• W1945841307 countsByYear W19458413072014 @default.
• W1945841307 countsByYear W19458413072015 @default.
• W1945841307 countsByYear W19458413072016 @default.
• W1945841307 countsByYear W19458413072017 @default.
• W1945841307 countsByYear W19458413072018 @default.
• W1945841307 countsByYear W19458413072019 @default.
• W1945841307 countsByYear W19458413072020 @default.
• W1945841307 countsByYear W19458413072021 @default.
• W1945841307 countsByYear W19458413072022 @default.
• W1945841307 countsByYear W19458413072023 @default.
• W1945841307 crossrefType "journal-article" @default.
• W1945841307 hasAuthorship W1945841307A5004846236 @default.
• W1945841307 hasAuthorship W1945841307A5005036709 @default.
• W1945841307 hasAuthorship W1945841307A5022703304 @default.
• W1945841307 hasAuthorship W1945841307A5029406825 @default.
• W1945841307 hasAuthorship W1945841307A5033331656 @default.
• W1945841307 hasAuthorship W1945841307A5050151766 @default.
• W1945841307 hasAuthorship W1945841307A5062849136 @default.
• W1945841307 hasAuthorship W1945841307A5089768127 @default.
• W1945841307 hasConcept C126322002 @default.
• W1945841307 hasConcept C134018914 @default.
• W1945841307 hasConcept C142724271 @default.
• W1945841307 hasConcept C168563851 @default.
• W1945841307 hasConcept C203092338 @default.
• W1945841307 hasConcept C204787440 @default.
• W1945841307 hasConcept C27081682 @default.
• W1945841307 hasConcept C2777180221 @default.
• W1945841307 hasConcept C2778384471 @default.
• W1945841307 hasConcept C2779306644 @default.
• W1945841307 hasConcept C2780323712 @default.
• W1945841307 hasConcept C2781308992 @default.
• W1945841307 hasConcept C2781413609 @default.
• W1945841307 hasConcept C555293320 @default.
• W1945841307 hasConcept C71924100 @default.
• W1945841307 hasConcept C90924648 @default.
• W1945841307 hasConceptScore W1945841307C126322002 @default.
• W1945841307 hasConceptScore W1945841307C134018914 @default.
• W1945841307 hasConceptScore W1945841307C142724271 @default.
• W1945841307 hasConceptScore W1945841307C168563851 @default.
• W1945841307 hasConceptScore W1945841307C203092338 @default.
• W1945841307 hasConceptScore W1945841307C204787440 @default.
• W1945841307 hasConceptScore W1945841307C27081682 @default.
• W1945841307 hasConceptScore W1945841307C2777180221 @default.
• W1945841307 hasConceptScore W1945841307C2778384471 @default.
• W1945841307 hasConceptScore W1945841307C2779306644 @default.
• W1945841307 hasConceptScore W1945841307C2780323712 @default.
• W1945841307 hasConceptScore W1945841307C2781308992 @default.
• W1945841307 hasConceptScore W1945841307C2781413609 @default.
• W1945841307 hasConceptScore W1945841307C555293320 @default.
• W1945841307 hasConceptScore W1945841307C71924100 @default.
• W1945841307 hasConceptScore W1945841307C90924648 @default.
• W1945841307 hasIssue "12" @default.
• W1945841307 hasLocation W19458413071 @default.
• W1945841307 hasLocation W19458413072 @default.
• W1945841307 hasOpenAccess W1945841307 @default.
• W1945841307 hasPrimaryLocation W19458413071 @default.
• W1945841307 hasRelatedWork W2006925617 @default.
• W1945841307 hasRelatedWork W2044435399 @default.
• W1945841307 hasRelatedWork W2115408777 @default.
• W1945841307 hasRelatedWork W2374444450 @default.
• W1945841307 hasRelatedWork W2460294411 @default.
• W1945841307 hasRelatedWork W2559748650 @default.
• W1945841307 hasRelatedWork W2964087648 @default.
• W1945841307 hasRelatedWork W3189964344 @default.
• W1945841307 hasRelatedWork W3204819581 @default.
• W1945841307 hasRelatedWork W4283826296 @default.

• next